Interpretation of WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents

doi:10.19982/j.issn.1000-6621.20220403

Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (1): 6-12.doi: 10.19982/j.issn.1000-6621.20220403

• Interpretation of Standard • Previous Articles Next Articles

Interpretation of WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents

Fan Lichao¹, Jiao Weiwei², Wu Haoyu¹, Shen Adong²(), Chen Yu¹()

¹Department of Student and Child Tuberculosis, Shenyang Tenth People’s Hospital,Shenyang 110044, China
²Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China

Received:2022-10-17 Online:2023-01-10 Published:2022-12-30
Contact: Shen Adong,Chen Yu E-mail:shenadong@bch.com.cn;yuchensyxk@163.com
Supported by:
Natural Science Foundation of Liaoning Province(2022-MS-432)

Abstract

Abstract:

On March 21, 2022, the World Health Organization (WHO) published the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents (2022 version Guideline), and provide guidance for the implementation of the guidance recommendations through the published implementation manual. The 2022 version Guideline standardizes the management of tuberculosis in children and adolescents based on the latest evidence-based medical evidence, and focuses on updating the use of Xpert Ultra as the initial diagnosis tool and rifampicin resistance detection tool for children and adolescents with tuberculosis; integrated treatment decision-making paths is enabled; 4-month treatment program is enabled for non-severe children; treatment program containing bedaquiline is enabled for multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB) children under the age of 6; among MDR/RR-TB children under 3 years of age, the treatment plan with delamanid can be used; the option of intensive treatment with a course of 6 months can be used for tuberculous meningitis; and the decentralized tuberculosis care model sinking to the grass-roots level and the integrated tuberculosis care model with family as the core can be used. The author now introduces the 2022 version Guideline and interprets the updated key points, aiming to provide reference for staff in the field of tuberculosis diagnosis and treatment in children and adolescents based on evidence.

Key words: Child, Adolescent, Tuberculosis, Consensus development conferences as topic

CLC Number:

R52
R725

Fan Lichao, Jiao Weiwei, Wu Haoyu, Shen Adong, Chen Yu. Interpretation of WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 6-12. doi: 10.19982/j.issn.1000-6621.20220403

References 6

[1]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[2]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization, 2022.
[3]	World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization, 2014.
[4]	World Health Organization. Roadmap towards ending TB in children and adolescents. 2nd ed. Geneva: World Health Organization, 2018.
[5]	World Health Organization. WHO Model List of Essential Medicines for Children-8th List, 2021, Geneva: World Health Organization,
[6]	Wolzak NK, Cooke ML, Orth H, et al. The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr, 2012, 58(6):491-495. doi:10.1093/tropej/fms031. doi: 10.1093/tropej/fms031. URL

[1]	Wang Qian, Wang Jia, Li Yuhong, Liu Eryong, Zhou Lin. Attach importance to childhood tuberculosis and care for children’s health [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 1-5.
[2]	He Xiaomou, Luo Hui, Ma Jinbao, Ren Fei, Zhao Ali, Yuan Rong. Effect of “trinity” care service on the multidrug-/rifampicin-resistant tuberculosis patients in the intensive phase [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 104-110.
[3]	Tao Liying, Xu Zheng, Zhao Xin, Li Yanyuan, Li Yamin, Xu Yan, Zhang Yanan, Gao Zhidong. Analysis of tuberculosis screening results among freshmen of high schools and below in Beijing,2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 111-115.
[4]	Shang Yuanyuan, Nie Wenjuan, Huang Hairong, Chu Naihui. Research status of drug resistance of antituberculosis drugs bedaquiline and clofazimine [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 116-122.
[5]	Wang Zeming, Shen Adong. Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 13-17.
[6]	Wang Zeming, Shen Adong. Interpretation of Social Organization Standard of Diagnosis of central nervous system tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 18-24.
[7]	Han Tingting, Liu Guizhen, Chen Qiuqi, Deng Guofang. Interpretation of Framework for collaborative action on tuberculosis and comorbidities [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 25-30.
[8]	Li Guilian, Fang Min, Jiang Jingwei, Wang Ruihuan, Qian Chengyu, Yu Jinjie, Cao Bin, Xu Da, Zhao Xiuqin, Li Machao, Liu Haican, Sun Lin, Zhu Yu, Wan Kanglin. Exploration for improving the culture-positive rate of Mycobacterium tuberculosis in gastric fluid specimens from pediatric patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 31-37.
[9]	Li Xiang, Fu Xuwen, Xu Yanling, Gan Wei, Qi Min, Huang Ying. The value of CT signs combined with peripheral blood eosinophils in differentiating pleuropulmonary paragonimiasis from pleural tuberculosis in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 38-44.
[10]	Chen Fang, Zhang Xiaofo, Zhou Haiyi, Zhang Feng, Wang Manzhi. Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 45-51.
[11]	Ren Fei, Ma Jinbao, Li Rong, Yang Han, Yang Hong, Wu Yanqin, Yang Xinjun, Dang Liyun. Efficacy and eligibility of high-dose moxifloxacin short-course regimen for rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 52-59.
[12]	Yu Meiling, Zhang Chenchen, Wei Wenjing, Zhao Yuchuan, Zhuo Wenji, Zheng Lei. Study on high-concentration p-aminosalicylic acid resistant Mycobacterium tuberculosis induced in vitro and the mutation sites [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 60-66.
[13]	Sheng Yunfeng, Qiu Meihua, Chen Yuanyuan, Sun Lifang, Zhen Libo. Research on mechanisms of dendritic cell miR-17 regulating naive CD4⁺T lymphocytes unevenly differentiating to Treg/Th17 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 67-72.
[14]	Wei Shuzhen, Zhao Yong, Lin Jian, Lin Shufang, Dai Zhisong. Analysis of genotype characteristics and drug resistance of Mycobacterium tuberculosis isolates in Fujian Province from 2017 to 2019 [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 73-78.
[15]	Xu Yinjuan, Zhao Guolian, Cui Xiaoli, Dang Liyun, Kang Lei, Zhou Yong. The application value of SAT-TB in monitoring the curative effect of patients with tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 79-84.

Interpretation of WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 6

Related Articles 15

Recommended Articles

Metrics

Comments